Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie M Brodmerkel

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Biotechnology|December 10, 2003
Transgenic animals in inflammatory disease modelsCarrie M Brodmerkel, Krishna Vaddi
Nature Biotechnology|July 13, 2011
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumabJacqueline M Benson, Clifford W Sachs, George Treacy, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344Carrie M Brodmerkel, Reid Huber, Maryanne Covington, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2010
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2Chu-Biao Xue, Anlai Wang, David Meloni, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Biotechnology|December 10, 2003
Transgenic animals in inflammatory disease modelsCarrie M Brodmerkel, Krishna Vaddi
Nature Biotechnology|July 13, 2011
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumabJacqueline M Benson, Clifford W Sachs, George Treacy, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 8, 2005
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344Carrie M Brodmerkel, Reid Huber, Maryanne Covington, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2010
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2Chu-Biao Xue, Anlai Wang, David Meloni, et al.
Pageof 1